These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21120328)

  • 1. [New medicines registered in Brazil: can they be considered as a therapeutic advance?].
    Gava CM; Bermudez JA; Pepe VL; dos Reis AL
    Cien Saude Colet; 2010 Nov; 15 Suppl 3():3403-12. PubMed ID: 21120328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance risk mitigation plans: action in public health to promote the safe use of medication.
    Botelho SF; Reis AM
    Cien Saude Colet; 2015 Dec; 20(12):3897-905. PubMed ID: 26691813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recall of substandard medicines in Brazil during the period 2010-2018.
    Oliveira CLCG; Machado VF; de Freitas Tavares H; Ribeiro GLM; Arrais PSD
    BMC Health Serv Res; 2023 Mar; 23(1):238. PubMed ID: 36899376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based process for decision-making in the analysis of legal demands for medicines in Brazil.
    Figueiredo TA; Osorio-de-Castro CG; Pepe VL
    Cad Saude Publica; 2013 Nov; 29 Suppl 1():S159-66. PubMed ID: 25402244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of new drugs registered in Brazil in view of the Unified Health System and the disease burden.
    Botelho SF; Martins MAP; Reis AMM
    Cien Saude Colet; 2018 Jan; 23(1):215-228. PubMed ID: 29267825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Judicialization of access to medicines in Minas Gerais state, Southeastern Brazil.
    Machado MA; Acurcio Fde A; Brandão CM; Faleiros DR; Guerra AA; Cherchiglia ML; Andrade EI
    Rev Saude Publica; 2011 Jun; 45(3):590-8. PubMed ID: 21445458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study.
    Zeitoun JD; Ross JS; Atal I; Vivot A; Downing NS; Baron G; Ravaud P
    BMJ Open; 2017 Dec; 7(12):e018587. PubMed ID: 29273664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Situation of lawsuits concerning the access to medical products by the Health Department of Santa Catarina State, Brazil, during the years 2003 and 2004].
    Pereira JR; dos Santos RI; do Nascimento Junior JM; Schenkel EP
    Cien Saude Colet; 2010 Nov; 15 Suppl 3():3551-60. PubMed ID: 21120343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections.
    Geyer ARC; Sousa VD; Silveira D
    PLoS One; 2018; 13(8):e0202084. PubMed ID: 30089162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The regulation of herbal medicines in Australia.
    Briggs DR
    Toxicology; 2002 Dec; 181-182():565-70. PubMed ID: 12505367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
    Mueller LL; Taketsuma Costa SM
    Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expert consensus (SBC/SBHCI) on the use of drug-eluting stents: recommendations of the Brazilian society of interventional cardiology/ Brazilian society of cardiology for the Brazilian public single healthcare system.
    Lima VC; Mattos LA; Caramori PR; Perin MA; Mangione JA; Machado BM; Coelho WM; Bueno RR
    Arq Bras Cardiol; 2006 Oct; 87(4):e162-7. PubMed ID: 17128305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Quality of over-the-counter medicines: a study with dipyrone brands commercialized in a drugstore in Cascavel city (Paraná, Brazil)].
    Knappmann AL; de Melo EB
    Cien Saude Colet; 2010 Nov; 15 Suppl 3():3467-76. PubMed ID: 21120334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
    Ghosh D; Skinner M; Ferguson LR
    Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites.
    Juhlin K; Karimi G; Andér M; Camilli S; Dheda M; Har TS; Isahak R; Lee SJ; Vaughan S; Caduff P; Norén GN
    Drug Saf; 2015 Apr; 38(4):373-82. PubMed ID: 25687792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.